Safety, Tolerability, Pharmacokinetic and Microbiological Investigation of GSK3882347 in Female Participants With Urinary Tract Infections

  • STATUS
    Recruiting
  • days left to enroll
    21
  • participants needed
    80
  • sponsor
    GlaxoSmithKline
Send
Updated on 7 October 2022
See if I qualify

Summary

This phase 1b study is a double-blind, double-dummy, nitrofurantoin-controlled study designed to evaluate microbiological response at the test of cure (ToC) visit along with safety, tolerability and pharmacokinetic (PK) response following daily oral dosing for 5 days of GSK3882347 in an adult female with uncomplicated urinary tract infections (uUTI). Comparator nitrofurantoin will be included in the study to ensure unbiased reporting of safety events. The study will be separated into 2 cohorts. Cohort 1 consists of an inpatient treatment period and PK analysis at frequent timepoints. Cohort 2 includes an outpatient treatment period and PK analysis conducted less frequently, at key trough timepoints.

Details
Condition Uncomplicated Urinary Tract Infections
Treatment Placebo, Nitrofurantoin, GSK3882347
Clinical Study IdentifierNCT05138822
SponsorGlaxoSmithKline
Last Modified on7 October 2022

Eligibility

 Yes No Not Sure

Inclusion Criteria

Participants must be greater than or equal to (>=)18 years of age and less than or equal to (<=)70 years
The participant has 2 or more of the following clinical signs and symptoms of uncomplicated urinary tract infections (uUTI) with onset less than or equal to (<=) 72 hours of the screening assessment: dysuria, frequency, urgency, or lower abdominal pain
Participant has nitrite and pyuria from a pretreatment clean-catch midstream urine sample
Participants with body mass index (BMI) greater than or equal to (>=) 19.0 kilograms per square meter (kg/m^2)
A female participant is eligible to participate who is not pregnant (as confirmed by a highly sensitive pregnancy test before the first dose of study intervention) or breastfeeding and one of the following conditions apply
Woman participant of non-childbearing potential (WONCBP) Or
Woman participant of childbearing potential (WOCBP) using a contraceptive method that is highly effective, with a failure rate of less than (<) 1 percentage (%), during the study intervention period
Capable of giving signed informed consent which includes compliance with the
requirements and restrictions listed in the informed consent form (ICF) and
protocol

Exclusion Criteria

The participant has a BMI greater to or equal (>=) 40.0 kg/ m^2 or a BMI >=35.0 kg/ m^2 with obesity related health conditions such as high blood pressure or uncontrolled diabetes (non-fasting glucose value >300 milligram/deciliter [mg/dL])
The participant is immunocompromised or has altered immune defenses that may predispose the participant to a higher risk of treatment failure and/or complications
The participant has symptoms known or suspected to be caused by another disease process, such as asymptomatic bacteriuria, overactive bladder, chronic incontinence, or chronic interstitial cystitis
The participant has an anatomical or physiological anomaly that predisposes the participant to UTIs or may be a source of persistent bacterial colonization, including calculi, obstruction of the urinary tract, primary renal disease, or neurogenic bladder, or the participant has a history of anatomical or functional abnormalities of the urinary tract
The participant has an indwelling catheter, nephrostomy, ureteral stent, or other foreign material in the urinary tract
The participant who, in the opinion of the investigator, has an otherwise complicated UTI, an active upper UTI (e.g., pyelonephritis, urosepsis), signs and symptoms onset >=96 hours before the screening assessment, or a temperature >=101 degree Fahrenheit (°F) (>=38 degree Celsius [°C]), flank pain, chills, or any other manifestations suggestive of upper UTI
The participant has anuria, oliguria, or significant impairment of renal function
The participant presents at enrollment with a suspected sexually transmitted infection
A positive confirmation of Coronavirus Disease 2019 (COVID-19) infection, or high clinical index of suspicion for COVID-19
The participant has received treatment with other systemic antimicrobials or systemic antifungals within 4 weeks before study entry
Regular alcohol consumption within 6 months prior to the study with an average weekly intake of >14 units for females and one unit is equivalent to approximately 8 g of alcohol: a half-pint (250 ml) of beer, one glass (125 mL) of wine or one (35 mL) measure of spirits
Unable to take nitrofurantoin. E.g. hypersensitivity to the active substance
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note